Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
In conclusions, a higher serum level of sCD26 is associated with a worse response to sitagliptin in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea therapy.
PMID: 22153807 [PubMed - in process] (Source: Translational Research : the journal of laboratory and clinical medicine)
METFORMIN HYDROCHLORIDEtablet, Extended Release [Rebel Distributors Corp]
Updated Date: Dec 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
